Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Evaluating Long-term-Outcome, Toxicity, Survival, and Quality-of-Life During Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients with Advanced Neuroendocrine Tumors

Trial Profile

A Study Evaluating Long-term-Outcome, Toxicity, Survival, and Quality-of-Life During Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients with Advanced Neuroendocrine Tumors

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Capecitabine (Primary) ; Lutetium-(177Lu)-oxodotreotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top